Hepatitis D drug, Hepcludex, receives approval by the European Commission
by Press Release from Outbreak News Today on (#56K0V)
What started off as basic research 25 years ago has now lead to a successfully approved drug: The entry blocker bulevirtide (brand name Hepcludex, formerly known as Myrcludex B), jointly developed by researchers from Heidelberg University Hospital (UKHD) and the Medical Faculty of Heidelberg, the DZIF and other partners, has now been approved by the [...]
The post Hepatitis D drug, Hepcludex, receives approval by the European Commission appeared first on Outbreak News Today.